Smith & Nephew SNATS (NYSE: SNN) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Smith & Nephew SNATS to similar companies based on the strength of its risk, valuation, dividends, earnings, profitability, institutional ownership and analyst recommendations.
Institutional & Insider Ownership
6.5% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 54.9% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Smith & Nephew SNATS and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew SNATS||N/A||N/A||N/A|
|Smith & Nephew SNATS Competitors||-101.23%||-92.70%||-30.32%|
Smith & Nephew SNATS pays an annual dividend of $0.61 per share and has a dividend yield of 1.7%. As a group, “Medical Devices & Implants” companies pay a dividend yield of 1.1% and pay out 36.3% of their earnings in the form of a dividend. Smith & Nephew SNATS has raised its dividend for 4 consecutive years.
This is a breakdown of current ratings and recommmendations for Smith & Nephew SNATS and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew SNATS||0||2||2||0||2.50|
|Smith & Nephew SNATS Competitors||110||728||1026||10||2.50|
Smith & Nephew SNATS currently has a consensus price target of $42.00, indicating a potential upside of 17.15%. As a group, “Medical Devices & Implants” companies have a potential upside of 38.27%. Given Smith & Nephew SNATS’s rivals higher probable upside, analysts plainly believe Smith & Nephew SNATS has less favorable growth aspects than its rivals.
Risk & Volatility
Smith & Nephew SNATS has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS’s rivals have a beta of 0.46, indicating that their average stock price is 54% less volatile than the S&P 500.
Valuation & Earnings
This table compares Smith & Nephew SNATS and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Smith & Nephew SNATS||$4.67 billion||$784.00 million||N/A|
|Smith & Nephew SNATS Competitors||$1.67 billion||$207.58 million||86.72|
Smith & Nephew SNATS has higher revenue and earnings than its rivals.
Smith & Nephew SNATS beats its rivals on 9 of the 14 factors compared.
Smith & Nephew SNATS Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.